Popular Articles

Abbott And AstraZeneca Submit New Drug Application To The FDA For CERTRIAD(TM), An Investigational Treatment For Mixed Dyslipidemia
Abbott (NYSE: ABT) and AstraZeneca announced that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia, a combination of two or more lipid abnormalities including high LDL- cholesterol (the "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). The NDA submission for this investigational compound, containing the active ingredients of CRESTOR(R) (rosuvastatin calcium) and TRILIPIX(R) (fenofibric acid), is supported by data from multiple studies, including efficacy and safety studies with the 5mg, 10mg and 20mg doses of rosuvastatin combined with fenofibric acid. Pending approval of the NDA, the treatment will be marketed as CERTRIAD(TM).
generic viagra online
Dramatic Increase In Social Isolation Cited By 2004 General Social Survey Is Disputed
A widely publicized analysis of social network size, which reported dramatically increasing social isolation when it was published in 2006, has sparked an academic debate in the August issue of the American Sociological Review (ASR), the flagship journal of the American Sociological Association.
News of the day
Risk Of Dialysis Access Failure Reduced By Combination Of Aspirin And Anti-Clotting Drug
For the first time, a combination of aspirin and the anti-platelet drug dipyridamole has been shown to significantly reduce blockages and extend the useful life of new artery-vein access grafts used for hemodialysis, according to a study by the Dialysis Access Consortium (DAC). The study, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, will be published in the May 21, 2009, New England Journal of Medicine.
Cardiovascular

Vitamin D Repletion Does Not Alter Urinary Calcium Excretion In Healthy Postmenopausal Women

UroToday.com - Vitamin D needs, especially in the northern latitudes where direct sunlight is unavailable for much of the year, are currently under scrutiny by members of both the scientific and medical communities. Vitamin D primarily plays a role in regulating calcium absorption in the gastrointestinal tract. However, epidemiologic and laboratory studies support the notion that vitamin D might play a role in chemoprevention - particularly of cancers of the colon, breast, ovarian, and prostate (Garland et al., Am J Public Health 2006;96:252-61) - immune modulation and prevention of certain autoimmune disorders (Cantorna et al., Exp Biol Med 2004;229:1136-1142), promoting bone integrity and preserving muscle mass (Montero-Odasso et al., Mol Aspects Med 2005;26:203-19), cardiovascular disease prevention (Wang et al., Circulation 2008;117:503-11), and prevention of all-cause mortality (Melamed et al., Arch Intern Med 2008;168:1629-37). Current vitamin D recommendations too low? The current recommended intake values for vitamin D were established in 1997 by the Institute of Medicine of The National Academies, which is responsible for publishing The Dietary Reference Intakes (DRIs), a set of nutrient recommendations for >40 essential macronutrients, vitamins, and minerals based on age, gender, and lifestage. In light of mounting evidence of both the frequency of low vitamin D status and newly-appreciated roles for vitamin D, and following pleas from such organizations as the Canadian Pediatric Society, the American Medical Association, and the American Academy of Pediatrics, a review of vitamin D needs was initiated earlier this year. The anticipated outcome of this review is 2010, at which time new recommendations for vitamin D are expected. To dose or not to dose: that is the question. As a growing number of individuals are reportedly supplementing with vitamin D in an effort to protect against various sequelae related to vitamin D insufficiency, it seems imperative to determine whether this practice should be recommended in calcium stone formers, especially as they may suffer from some of the same comorbidities purported to be managed with vitamin D intakes above the current recommendations. For many years, calcium stone formers have been instructed to avoid vitamin D supplementation for fear that it may contribute to or exacerbate hypercalciuria. However, data supporting this recommendation are scarce. We ascertained the safety of vitamin D repletion in vitamin D insufficient post-menopausal women with respect to 24-h urinary calcium excretion. We undertook this evaluation as a first step towards the planning and implementation of a vitamin D repletion/supplementation study in stone formers. Vitamin D repletion did not alter urinary calcium excretion. Calcium absorption increased nominally (3%, p = 0.04) in post-menopausal women after vitamin D repletion with 50,000 IU ergocalciferol daily for 15 days, without a change in urinary calcium excretion. Such data suggest that vitamin D repletion might also be safe in calcium stone formers with and without hypercalciuria. While post-menopausal women carry a higher risk for urolithiasis than younger women and are thus a good model for urolithiasis research, the safety of higher vitamin D intakes in stone formers should be rigorously assessed. This information is crucial if we are to make evidence-based recommendations about vitamin D to calcium stone formers, especially if vitamin D recommendations are increased, as is expected, within the next year. Written by Kristina L. Penniston, PhD, and Karen E. Hansen, MD as part of Beyond the Abstract on UroToday.com. UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright - 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):